Marnetegragene autotemcel is under clinical development by Rocket Pharmaceuticals and currently in Phase II for Leukocyte Disorders (White Blood Cell Disorders). According to GlobalData, Phase II drugs for Leukocyte Disorders (White Blood Cell Disorders) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Marnetegragene autotemcel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Marnetegragene autotemcel overview
RPL-201 is under development for the treatment of leukocyte adhesion deficiency (LAD) type 1. The therapeutic candidate constitutes patient-derived hematopoietic stem cells modified with a lentiviral vector containing the CD18 gene. It is administered through intravenous route. It acts by targeting integrin beta 2.
Rocket Pharmaceuticals overview
Rocket Pharmaceuticals (Rocket Pharma), formerly Inotek Pharmaceuticals Corp is a clinical-stage biopharmaceutical company. It focuses on
For a complete picture of Marnetegragene autotemcel’s drug-specific PTSR and LoA scores, buy the report here.